ReviewBeilstein journal of nanotechnology2025
Better together: biomimetic nanomedicines for high performance tumor therapy.
Review in Beilstein journal of nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy.International journal of nanomedicine · 2026Review
- Micro- and nanoscale effects in biological and bioinspired materials and surfaces.Beilstein journal of nanotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of nanotechnology offers a promising avenue for enhancing cancer treatment outcomes. In this context, biomimetic nanoparticles have emerged as an exciting frontier in the field of biomedicine. These nanoparticles can emulate essential biological functions, drawing from an abundant reservoir of cellular capabilities. This includes engaging in biological binding, precise homing to tumor sites, and interaction with immune cells. These inherent traits endow biomimetic nanoparticles with a suite of intelligent features, including biocompatibility, low immunogenicity, reduced toxicity, immune evasion, prolonged circulation, homotypic binding, enhanced tumor targeting, and the capability of precise delivery. By integrating biologically inspired coatings derived from cell membranes with nanoparticle cores, these carriers become highly versatile vessels for encapsulating a wide array of therapeutic agents. As a result, they are being extensively harnessed for the precise delivery of drugs and genes, underpinning numerous biomedical applications. This discussion delves into the challenges and opportunities presented by biomimetic nanoparticles and offers a comprehensive exploration of their fundamentals and recent breakthroughs, with an eye towards clinical translation. By bridging the gap between scientific innovation and clinical utility, biomimetic nanoparticles hold great promise for advancing the field of cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.